Last updated: February 13, 2026
What is the Drug Associated with NDC 51672-4133?
NDC 51672-4133 corresponds to Brodalumab, a monoclonal antibody developed by Eli Lilly for the treatment of moderate to severe plaque psoriasis. It is marketed under the brand name Siliq in the U.S. and approved by the FDA in 2017. Brodalumab acts as an interleukin-17 receptor A (IL-17RA) antagonist.
What is the Current Market Environment?
Market Size & Demand
- The global psoriasis treatment market was valued at approximately USD 11 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8–10% through 2028 [1].
- In the U.S., around 7.5 million adults have psoriasis, with approximately 20–30% classified as severe cases suitable for biologic therapy.
- Brodalumab accounts for a small, yet significant share of biologics targeting IL-17 pathways; its market share lags behind competitors such as secukinumab (Cosentyx) and ixekizumab (Taltz).
Competitive Landscape
- Major competitors include:
- Secukinumab (Cosentyx): Estimated 40% market share among IL-17 inhibitors.
- Ixekizumab (Taltz): Approximate 30% market share.
- Brodalumab (Siliq): Estimated at 10-15% of IL-17 biologic sales.
- Lilly's market penetration is constrained by prior safety concerns (notably suicidal ideation) and limited clinical usage compared to competitors.
Pricing Strategy & Market Penetration
- The wholesale acquisition cost (WAC) for Brodalumab in 2023 is around $6,800–$7,200 per monthly injection [2], similar to other IL-17 inhibitors.
- Commercial insurance rebates and discounts substantially reduce net price; estimated net effective price ranges from $4,000 to $5,000 per month.
What Are the Price Projections?
Short-term (Next 1-2 Years)
- No major price adjustments are expected solely due to market conditions.
- Given increased competition and payer pressure, Lilly may implement modest discounts or rebates to maintain market share.
- Price stability is likely until new formulations or indications emerge.
Medium-term (3-5 Years)
- Entry of biosimilars or authorized generics could pressure list prices downward by 10–20%.
- Lilly’s strategic pricing to sustain exclusivity may involve value-based pricing models, especially if new indications, such as psoriatic arthritis, expand the label.
Long-term (5+ years)
- Biosimilar competition from European or emerging market entrants could further erode price points.
- Assuming market maturation, list prices may decline by 30–50% over a decade, but net prices could decline less due to rebates.
Future Market Trends and Risks
- Potential approvals of biosimilars and emerging competitors could cut prices and market share.
- Safety profile and real-world effectiveness could influence payer and clinician preferences.
- New indications, such as inflammatory bowel disease, could introduce pricing flexibility and higher market value.
Summary Table of Price Projections
| Timeframe |
Expected Price Range (list) |
Expected Price Range (net) |
Key Factors |
| 2023–2024 |
$6,800–$7,200 per injection |
$4,000–$5,000 per injection |
Competitive pressures, rebate strategies |
| 2025–2027 |
Slight decrease or stable |
Slight decrease or stable |
Biosimilar entry, market saturation |
| 2028–2033 |
30–50% reduction from current |
Similar reduction expected |
Biosimilar proliferation, price erosion |
Key Takeaways
- Brodalumab’s market share remains limited due to safety concerns and established competition.
- Prices are relatively stable in the short term but may decline significantly with biosimilar competition.
- Payer negotiation and formulary strategies heavily influence net pricing.
- When evaluating investment or R&D, consider the potential impact of biosimilar entry and expansion into other indications.
FAQs
1. How does the safety profile of brodalumab affect its market?
Safety concerns, notably suicidal ideation reports, have limited its adoption and market share relative to competitors with similar efficacy profiles.
2. What are the main competitive threats to brodalumab?
Biosimilars, similar IL-17 inhibitors like secukinumab and ixekizumab, and new therapeutics targeting alternative pathways pose primary threats.
3. How does biosimilar entry affect pricing?
Biosimilar competition typically reduces list prices by 20–50%, though net prices depend on rebate levels and market penetration.
4. Are there indications beyond psoriasis that could influence pricing?
Yes, ongoing studies explore use for psoriatic arthritis and Crohn’s disease, which could enhance value and influence pricing strategies.
5. What is the outlook for brodalumab’s market share?
Market share is likely to plateau or decline over the next 3-5 years as competitors expand and biosimilars enter, unless new indications or formulations are introduced to differentiate the product.
References
[1] MarketResearch.com, "Psoriasis Treatment Market Outlook 2023–2028," 2023.
[2] GoodRx, "Biologic drug prices," 2023.
